Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation.

Masahide HaradaYuji MotoikeYoshihiro NomuraAsuka NishimuraMasayuki KoshikawaKazuhiro MurayamaYoshiharu OhnoEiichi WatanabeHideo IzawaYukio Ozaki

Published in: Journal of arrhythmia (2020)

Switching to dabigatran on the day of AF ablation decreases preclinical thromboembolic events with similar bleeding risk to uninterrupted factor Xa inhibitors.

Keyphrases

atrial fibrillation
direct oral anticoagulants
catheter ablation
left atrial
left atrial appendage
oral anticoagulants
heart failure
percutaneous coronary intervention
venous thromboembolism
radiofrequency ablation
coronary artery disease
mesenchymal stem cells
mitral valve
breast cancer risk